Atara Biotherapeutics, Inc.

ATRA Healthcare Biotechnology

Atara Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $120.8 million, down 6.33% from fiscal 2024. In the quarter to June 2026, revenue fell 96.4%, EPS fell 260.0% and free cash flow grew 52.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

9.18 0.47 −4.87%
Market cap
$96.9M
P/E
0.0×
Fwd P/E
−8.4×
Dividend yield
—
F-score
5/9
Altman Z
−125.91
Beneish M
16.88
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 5 3 3
ROE
(36.80%) (48.15%) 20.49% 46.33%
ROA
27.07% 50.55% (23.08%) (57.62%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
4,482.95% (1,239.59%) (143.81%) (248.19%)
Average Days of Receivables
4.60 3.79 0.00 18.74
Free Cash Flow per Share
(5.12) (3.99) (1.84) (1.46)
Free Cash Flow
(69.41) (50.08) (25.87) (21.89)
Capital Expenditures
0.30 0.86 — —
Other line items
Cash ROIC
302.81% 166.83% 89.37% 80.72%
Accounts Receivable Turnover
70.09 93.33 0.00 6.88
Accounts Payable Turnover
22.65 9.44 0.89 0.41
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
4.16 2.19 259.20 563.22
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
43.70% 31.00% 43.98% 67.99%
Selling, General and Administrative Expense of Revenue
20.68% 21.74% 79.41% 253.07%
Share Based Compensation of Revenue
9.27% 8.07% 27.19% 62.72%
Interest Coverage
6.70 9.46 (1.75) (5.04)
Operating CF/Net income
(2.98) (1.56) 2.73 1.31
Depreciation/Fixed assets
21.31 32.53 6.36 2.44
Capex/Depreciation
0.10 0.36 0.00 0.00
Revenue per Share
11.20 9.63 1.64 0.41
Operating CF per Share
(5.14) (4.06) (1.84) (1.46)
Capex per Share
0.02 0.07 0.00 0.00
Capex to Sales
0.00 (0.01) 0.00 0.00

Fold the line items

Columns are period end dates